Rezdiffra (Resmetirom) and Warfarin Interaction: Safety, Monitoring, and Dose Adjustment
Resmetirom (brand name Rezdiffra) is an oral, liver-directed thyroid hormone receptor-beta agonist approved by the FDA in March 2024 for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis, used together with diet and exercise. Warfarin (brand names Coumadin, Jantoven) is a vitamin K antagonist anticoagulant with a narrow therapeutic index, dosed to a target INR. This article addresses the interaction between the two: what is established, what is pharmacologically plausible but not directly demonstrated in the published record we reviewed, and what a prescriber or pharmacist still needs to verify before adjusting a patient's regimen.
Direct answer: Resmetirom is a CYP2C9 inhibitor, and CYP2C9 is the principal enzyme that clears the more potent S-enantiomer of warfarin, so co-administration has a plausible pharmacologic basis for raising INR. The FDA-approved Rezdiffra label addresses interactions with CYP2C9 substrates and recommends increased INR monitoring when warfarin is combined with resmetirom (verify exact wording and any specified dose-adjustment range against the current label, since we did not extract a verbatim numeric adjustment from a confirmed primary source). No published trial we identified reports warfarin-specific bleeding or INR outcome data from patients co-treated with resmetirom, so the magnitude of the effect in practice is not established, only the direction (increased anticoagulation) is pharmacologically expected.
Why this pairing comes up in practice
MASH patients frequently carry cardiovascular and thromboembolic comorbidity, including atrial fibrillation, venous thromboembolism, and mechanical heart valves, any of which can put a patient on warfarin. As resmetirom becomes a standard MASH therapy for patients with significant fibrosis, clinicians will increasingly need to manage it alongside existing anticoagulation. This is a practical prescribing question, not a rare edge case, even though dedicated interaction studies in this exact population are limited.
The pharmacologic mechanism
Warfarin is dosed as a racemic mixture. The S-enantiomer is substantially more potent as an anticoagulant than the R-enantiomer, and S-warfarin clearance depends heavily on CYP2C9. Resmetirom inhibits CYP2C9. When a CYP2C9 inhibitor is added to a stable warfarin regimen, the general pharmacologic expectation, well established across many other CYP2C9 inhibitors such as fluconazole and amiodarone, is reduced S-warfarin clearance, rising plasma concentration, and a higher INR.
Both resmetirom and warfarin are highly protein-bound. Protein-binding displacement alone rarely produces sustained clinical effects, but combined with enzyme inhibition it could plausibly amplify free warfarin concentration transiently during the first days of co-administration. This is a mechanistic hypothesis based on general pharmacokinetic principles, not a finding demonstrated for this specific drug pair in a published study we could verify.
Resmetirom's selective thyroid receptor-beta agonism is also worth flagging: thyroid status is a known modifier of warfarin sensitivity in hyperthyroid patients through accelerated clotting-factor catabolism. Resmetirom is selective for hepatic THR-beta and is not expected to produce systemic hyperthyroidism at approved doses, but the theoretical possibility of a secondary effect on warfarin sensitivity through this pathway has not been separately studied and should be treated as speculative.
What is established, what is plausible, and what is not established
| Status | Claim | Basis |
|---|---|---|
| Established | Resmetirom is an inhibitor of CYP2C9 | FDA-approved labeling addresses CYP2C9 substrate interactions; verify exact enzyme-inhibition language and recommended action against the current label PDF |
| Established | S-warfarin, the more potent enantiomer, is cleared predominantly by CYP2C9 | Long-standing, textbook-level warfarin pharmacology; independent of resmetirom-specific data |
| Established | Warfarin has a narrow therapeutic index and requires INR-guided dosing regardless of concomitant drugs | Standard anticoagulation management, per warfarin labeling |
| Plausible, not directly demonstrated for this pair | Combined CYP2C9 inhibition and albumin-binding competition could produce an early, transient exaggeration of the interaction beyond enzyme inhibition alone | General pharmacokinetic principle for highly protein-bound drug pairs; not a resmetirom-warfarin-specific finding |
| Plausible, not directly demonstrated | A specific empiric warfarin dose reduction (commonly cited ranges of roughly 10 to 25 percent for moderate CYP2C9 inhibitors) applies to resmetirom | Extrapolated from experience with other moderate CYP2C9 inhibitors, not a resmetirom-specific validated figure |
| Not established | The real-world magnitude of INR change, time course, or bleeding event rate when resmetirom is added to stable warfarin therapy | No published trial-level or observational dataset we identified reports warfarin-specific outcomes in resmetirom-treated patients; the pivotal phase 3 program was not designed to answer this question as a prespecified endpoint |
| Not established | Whether thyroid receptor-beta agonism meaningfully alters warfarin sensitivity independent of CYP2C9 inhibition | Theoretical extension from hyperthyroidism literature; not tested for resmetirom specifically |
| Needs verification | Exact resmetirom half-life, time to steady state, and any label-specified warfarin dose-adjustment language | Should be confirmed directly against the current FDA-approved Rezdiffra prescribing information before use in clinical decision-making or patient materials |
INR monitoring: a reasonable approach, not a validated protocol
There is no published, resmetirom-specific monitoring trial that establishes an optimal INR-check schedule. The approach below reflects standard practice for adding any moderate CYP2C9 inhibitor to stable warfarin therapy, and should be treated as site judgment pending confirmation from the current product labeling and the patient's anticoagulation care team, not as a guideline recommendation specific to resmetirom.
Before starting resmetirom: confirm the patient's INR is stable in range (commonly a run of consecutive values within target) and document the target range for their indication.
Early phase: check INR within the first several days after starting resmetirom, then at short intervals (for example weekly) through the first month, since enzyme inhibition effects typically build as a new drug reaches steady state and the warfarin response lags further behind that.
After stability is reconfirmed: return to the patient's usual INR monitoring interval. Restart intensive monitoring after any dose change to either drug.
If resmetirom is stopped: CYP2C9 inhibition is removed, warfarin clearance can increase, and INR may fall toward subtherapeutic. Recheck INR on a similar short-interval schedule after discontinuation, with warfarin dose increases guided by results, not assumed in advance.
Any warfarin dose change, whether preemptive or reactive, should be confirmed with a follow-up INR check within about a week. Empiric dose changes without monitoring are not appropriate for a narrow-therapeutic-index drug.
Other CYP2C9 substrates to review
Warfarin is not the only drug affected if resmetirom inhibits CYP2C9. A full medication reconciliation matters for any MASH patient starting resmetirom.
| Drug class or agent | Plausible consequence of CYP2C9 inhibition |
|---|---|
| Warfarin | Reduced clearance of the active S-enantiomer, higher INR |
| Losartan | Reduced conversion to its active metabolite, potentially lower antihypertensive effect |
| Phenytoin | Reduced clearance, higher levels, neurotoxicity risk |
| Sulfonylureas (glipizide, glimepiride) | Reduced clearance, higher hypoglycemia risk |
| NSAIDs metabolized by CYP2C9 (e.g., celecoxib) | Higher exposure, higher bleeding or GI risk |
Resmetirom's labeling also addresses increased rosuvastatin exposure through a transporter-mediated mechanism separate from CYP2C9; verify the current label for the specific statins and monitoring advice involved, since transporter-based interactions are not interchangeable with CYP2C9 effects.
Anticoagulant alternatives when warfarin can be replaced
For patients who have not yet started anticoagulation, or whose indication allows a switch, direct oral anticoagulants generally rely on CYP3A4 or non-CYP clearance rather than CYP2C9, which in principle avoids this specific interaction pathway. This is a general pharmacologic distinction, not a claim that DOACs are interaction-free with resmetirom; any switch should be evaluated against the patient's specific indication, renal function, and bleeding risk profile with their anticoagulation prescriber.
Warfarin generally cannot be replaced in patients with mechanical heart valves, where current cardiology guidance does not support DOAC use. These patients should be co-managed with a hematologist or anticoagulation clinic when resmetirom is being considered, given both the mechanical-valve requirement for warfarin and the added CYP2C9 interaction risk.
Special populations
Advanced fibrosis (F3 or cirrhotic). Impaired hepatic synthetic function can independently increase warfarin sensitivity by reducing clotting factor production. Combining this with resmetirom's CYP2C9 inhibition could plausibly produce a larger INR shift than in a patient with earlier-stage fibrosis, though this compounding effect has not been separately quantified. The pivotal resmetirom fibrosis trial did not include decompensated cirrhotic patients, so data in that population specifically is limited.
CYP2C9 genetic variants. Patients who are CYP2C9 intermediate or poor metabolizers already clear S-warfarin more slowly and typically require lower baseline warfarin doses. Adding a CYP2C9 inhibitor on top of reduced-function genotype is a recognized pattern of amplified sensitivity for other CYP2C9 inhibitors, and the same logic plausibly applies to resmetirom, though it has not been separately studied for this pair. Pharmacogenomic testing, where available, can inform how cautious to be.
Older adults. Age-related increases in warfarin sensitivity and bleeding risk are well established independent of resmetirom, and argue for closer monitoring and coordination with an anticoagulation service when starting resmetirom in this group.
Patient counseling points
- Report bleeding signs promptly: unusual bruising, bleeding gums, nosebleeds lasting more than about ten minutes, blood in urine or stool, dark or tarry stools, or bleeding from cuts that will not stop.
- Keep INR appointments during the first weeks after starting or stopping resmetirom. This is the period when the interaction, if it occurs, is most likely to shift the INR.
- Keep dietary vitamin K intake roughly consistent from week to week rather than trying to avoid vitamin K entirely, since large swings in intake independently destabilize INR.
- Make sure every prescriber managing the warfarin dose, not only the clinician prescribing Rezdiffra, knows both drugs are being taken together.
- Take resmetirom with food, per its labeling, for absorption; this is a separate instruction from warfarin timing.
When to seek urgent care
Heavy or uncontrolled bleeding, blood in vomit or stool, sudden severe headache, or any major trauma while on warfarin warrants emergency evaluation regardless of what other medications are involved. A markedly elevated INR found on routine testing should be managed under the direction of the prescribing or anticoagulation clinic, not adjusted by the patient independently.
Checklist for co-administration
| Step | Action |
|---|---|
| 1 | Confirm INR has been stable in range before adding resmetirom |
| 2 | Discuss with the anticoagulation prescriber whether a preemptive dose reduction is appropriate, rather than applying a fixed percentage automatically |
| 3 | Recheck INR within the first several days of starting resmetirom |
| 4 | Continue short-interval INR checks through at least the first month |
| 5 | Adjust warfarin dose based on INR results, not on a schedule alone |
| 6 | Return to standard monitoring only after INR has been stable for several consecutive checks |
| 7 | Notify the anticoagulation clinic at initiation and at any dose change |
| 8 | Re-monitor INR on a similar short-interval schedule if resmetirom is discontinued |
| 9 | Verify the current Rezdiffra label directly for any specific interaction language before finalizing a plan |
Questions this article can answer
Can resmetirom and warfarin be taken together at all? Yes, in principle, but the combination requires closer INR monitoring than warfarin alone because of a plausible pharmacokinetic interaction; it is not an absolute contraindication.
Does resmetirom raise or lower INR? The expected direction, based on CYP2C9 inhibition reducing S-warfarin clearance, is a rise in INR. This is a mechanistic expectation, not a measured effect from a published trial in this specific combination.
Is there a proven warfarin dose reduction percentage for starting resmetirom? No validated, resmetirom-specific figure was identified in the sources reviewed. Commonly cited ranges for other moderate CYP2C9 inhibitors are used as a starting point for clinical judgment, guided entirely by follow-up INR results.
What happens to INR if resmetirom is stopped? Removing the inhibitor should allow warfarin clearance to normalize, which can lower INR toward subtherapeutic levels; monitoring after discontinuation is as important as monitoring after initiation.
Evidence boundary
What is established: resmetirom's classification as a CYP2C9 inhibitor and warfarin's dependence on CYP2C9 for clearance of its active enantiomer are both grounded in accepted pharmacology and in FDA-approved labeling addressing CYP2C9 substrate interactions. What is plausible but unproven: the exact magnitude of INR change, the value of any specific empiric dose-reduction percentage, and a secondary effect through thyroid receptor-beta signaling. What is not established: bleeding or INR outcome data from patients actually co-treated with resmetirom and warfarin, since no controlled trial or observational study addressing this pairing directly was identified. Post-marketing adverse event reporting through the FDA's MedWatch program is one avenue for this evidence gap to close over time, and clinicians who observe INR instability in a co-treated patient should consider reporting it.
References
- U.S. Food and Drug Administration. Rezdiffra (resmetirom) prescribing information. Approved March 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
- U.S. Food and Drug Administration. Coumadin (warfarin sodium) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program